利尔化学股份有限公司 证券代码：002258 证券简称：利尔化学 利尔化学股份有限公司投资者关系活动记录表 编号：2023-02 投资者关系活  特定对象调研 □分析师会议 动类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内 容） 参与单位名称 东北证券：陈俊杰、孙鹏程；景林资产：蒋文超；淳阳基金： 及人员姓名 周彪。 时间 2023年11月16日 地点 公司会议室 上市公司接待 副总经理/董事会秘书：刘军 人员姓名 董事会办公室：马媛 1、公司精草铵膦项目建设进展？ 答：湖南津市2万吨/年酶法精草铵膦项目已经投产， 生产情况正常；荆州1万吨/年生化法精草铵膦项目已于今 年上半年开始建设，建设进程顺利，预计明年内投产。 ...

Financial Performance - The company's revenue for Q3 2023 was ¥1,537,231,043.15, a decrease of 42.30% compared to the same period last year[5] - Net profit attributable to shareholders was ¥80,269,093.00, down 81.94% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥72,707,752.04, reflecting an 83.24% decline compared to the previous year[5] - The total operating revenue for the third quarter of 2023 was CNY 6,006,422,528.32, a decrease of 22.4% compared to CNY 7,742,484,720.81 in the same period last year[18] - The net profit for Q3 2023 was CNY 707,628,843.99, a decrease of 57.7% compared to CNY 1,672,292,899.76 in Q3 2022[20] - Operating profit for Q3 2023 was CNY 831,453,910.63, down 58.3% from CNY 1,993,816,319.08 in the same period last year[20] - Revenue from sales of goods and services received in Q3 2023 was CNY 4,953,454,919.11, a decline of 23.1% from CNY 6,435,395,874.28 in Q3 2022[21] - The total profit for Q3 2023 was CNY 829,179,957.13, a decrease of 58.3% from CNY 1,981,137,142.83 in Q3 2022[20] - Basic earnings per share for Q3 2023 were CNY 0.6996, a decrease of 65.3% from CNY 2.0147 in Q3 2022[20] - The total comprehensive income for Q3 2023 was CNY 707,628,843.99, down 57.7% from CNY 1,672,292,899.76 in Q3 2022[20] Assets and Liabilities - The total assets at the end of the reporting period reached ¥14,002,280,821.62, an increase of 8.83% from the end of the previous year[5] - Total assets increased to CNY 14,002,280,821.62 from CNY 12,866,345,708.15, showing a growth of 8.8%[16] - Total liabilities rose to CNY 5,319,239,048.21 from CNY 4,483,335,442.13, an increase of 18.6%[16] - The company's non-current liabilities increased significantly to CNY 2,176,913,648.49 from CNY 885,372,764.13, marking a rise of 146.5%[16] Cash Flow - Cash flow from operating activities for the year-to-date was ¥337,935,268.23, a significant decrease of 80.84%[5] - The net cash flow from operating activities for Q3 2023 was CNY 337,935,268.23, a significant decrease of 81.9% compared to CNY 1,764,036,388.26 in Q3 2022[21] - The net cash flow from financing activities for Q3 2023 was CNY 933,970,558.58, compared to a net outflow of CNY 455,088,763.03 in Q3 2022[22] - Cash and cash equivalents decreased to CNY 1,100,717,665.72 from CNY 1,409,008,134.72, reflecting a decline of 21.8%[14] - Cash and cash equivalents at the end of Q3 2023 were CNY 1,079,179,442.83, a decrease from CNY 1,197,101,282.74 at the end of Q3 2022[22] Shareholder Information - The company’s major shareholders include Sichuan Jiuyuan Investment Holding Group Co., Ltd. with a 23.78% stake[11] - The company recorded a total of 54,082 common shareholders at the end of the reporting period[11] Operational Metrics - The total operating costs amounted to CNY 5,180,599,626.07, down from CNY 5,773,982,257.76, indicating a reduction of 10.3% year-over-year[18] - Accounts receivable decreased to CNY 1,295,562,611.55 from CNY 1,588,107,170.85, a reduction of 18.4%[15] - Inventory levels decreased to CNY 1,483,655,674.10 from CNY 1,709,758,816.00, representing a decline of 13.2%[15] - The company reported a 49.21% increase in prepayments, totaling ¥13,344.84 million, primarily due to increased operational prepayments[10] - Short-term borrowings increased by 110.73% to ¥27,915.89 million, attributed to new short-term loans taken during the period[10] Research and Development - Research and development expenses in Q3 2023 amounted to CNY 243,696,434.27, down 10.3% from CNY 271,644,374.07 in Q3 2022[20] - The company is focusing on expanding its market presence and developing new products, although specific figures were not disclosed in the report[15]

2023 年 10 月 24 日，利尔化学股份有限公司（以下简称"公司"） 第六届董事会第十二次会议以通讯表决的方式召开，会议通知于 2023 年 10 月 19 日以电子邮件方式送达。应出席会议的董事 9 人，实际出 席会议的董事 9 人。会议程序符合《公司法》和公司章程的规定。会议 由公司董事长尹英遂主持，经过各位董事认真审议，形成如下决议： 1、会议以 9 票同意，0 票弃权，0 票反对的结果，审议通过了《公 司 2023 年第三季度报告》。 证券代码：002258 证券简称：利尔化学 公告编号：2023-027 利尔化学股份有限公司 第六届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确 和完整，没有虚假记载、误导性陈述或重大遗漏。 特此公告。 利尔化学股份有限公司 董事会 2023 年 10 月 25 日 《公司 2023 年第三季度报告》刊登于 2023 年 10 月 25 日的中国 证券报和巨潮资讯网。 2、会议以 9 票同意，0 票弃权，0 票反对的结果，审议通过了《关 于公司内部组织机构调整的议案》。根据公司发展需要，为完善集团化 管控，会议同意公司设立生产运营 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥4,469,191,485.17, a decrease of 11.99% compared to ¥5,078,112,991.44 in the same period last year[24]. - The net profit attributable to shareholders was ¥479,689,916.47, down 54.21% from ¥1,047,583,941.10 year-on-year[24]. - The net cash flow from operating activities was ¥317,095,328.07, reflecting a significant decline of 75.54% compared to ¥1,296,536,529.40 in the previous year[24]. - Basic earnings per share decreased to ¥0.5993, down 57.74% from ¥1.4181 in the same period last year[24]. - The company reported a significant decrease in net profit after deducting non-recurring gains and losses, which was ¥481,350,115.74, down 54.19% from ¥1,050,698,840.97 year-on-year[24]. - The company's operating revenue for the reporting period was approximately ¥4.47 billion, a decrease of 11.99% compared to ¥5.08 billion in the same period last year, primarily due to a significant decline in the prices of core products[48]. - The company reported a total operating cost of CNY 3,741,055,116.65 for the first half of 2023, an increase of 1.5% compared to CNY 3,686,264,809.79 in the first half of 2022[167]. - The company’s financial expenses showed a significant improvement, with a net financial income of CNY 14,771,121.62 in the first half of 2023 compared to a loss of CNY 49,652,855.78 in the same period of 2022[168]. Assets and Liabilities - Total assets at the end of the reporting period were ¥13,590,819,972.61, an increase of 5.63% from ¥12,866,345,708.15 at the end of the previous year[24]. - The company's total liabilities increased to CNY 1,867,528,030.88 in the first half of 2023 from CNY 2,086,923,187.74 in the same period of 2022, representing a reduction of 10.5%[168]. - Long-term borrowings increased to ¥1,629,705,061.75, accounting for 11.99% of total liabilities, up from 4.35% last year[53]. - Total current assets decreased from CNY 5,157,349,061.32 to CNY 4,546,308,061.88, a decline of approximately 11.8%[159]. - Total non-current assets increased from CNY 7,708,996,646.83 to CNY 9,044,511,910.73, an increase of approximately 17.3%[161]. Market and Industry Trends - The global pesticide market size increased from $35.575 billion in 2006 to $87.7 billion in 2022, with a compound annual growth rate (CAGR) of approximately 5.80%[32]. - The domestic pesticide industry is undergoing significant transformation, with a focus on green pesticides and stricter environmental regulations[34]. - The company's main product, glyphosate, is experiencing a decline in price, impacting overall performance[36]. - The demand for the company's high-efficiency, low-toxicity pesticides is expected to rise due to the promotion of genetically modified crops[35]. - The integration of major international agricultural companies has led to a more concentrated market for upstream intermediates and active ingredients[33]. Research and Development - Research and development investment increased by 14.88% to approximately ¥201.76 million, reflecting the company's commitment to innovation[48]. - The company is focusing on strategic acquisitions to enhance its product offerings and market share in the chemical industry[181]. - The company has allocated 15.8 million for research and development in the first half of 2023, aiming to enhance product innovation[184]. Environmental Compliance - The company has established comprehensive waste treatment facilities to minimize negative environmental impacts[87]. - The company achieved compliance with emission standards for various pollutants, including 40.28 tons/year of sulfur dioxide and 163.73 tons/year of nitrogen oxides[92]. - The company has implemented a comprehensive environmental self-monitoring plan, with all monitoring data meeting national and local standards, and no instances of exceeding discharge limits reported[99]. - The company has made significant investments in emission control technologies to enhance environmental performance[92]. - The company has increased its environmental protection investments, ensuring compliance with stricter regulations, which may impact profitability[74]. Strategic Initiatives - The company plans to expand its market presence by launching new products and enhancing its research and development capabilities in the upcoming quarters[180]. - The company aims to mitigate foreign exchange risks through forward foreign exchange contracts, which resulted in losses due to significant fluctuations in the USD exchange rate during the reporting period[64]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[184]. Shareholder Information - The annual shareholders' meeting had a participation rate of 50.44% on March 22, 2023[80]. - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[82]. - The total number of common shareholders at the end of the reporting period is 58,262[147]. - The largest shareholder, Sichuan Jiuyuan Investment Holding Group Co., Ltd., holds 23.78% of the shares, totaling 190,376,009 shares[148]. Risk Factors - The company faces various risks including market competition, raw material supply and price fluctuations, and environmental risks, which investors should be aware of[5]. - Safety production risks remain a concern due to the nature of materials used in production, and the company emphasizes enhancing safety management and emergency response capabilities[75]. - Raw material costs significantly affect operating costs and gross margins, with increased supply but also rising procurement challenges due to demand fluctuations[72].

利尔化学股份有限公司 独立董事对有关事项的独立意见 经公司 2021 年度股东大会审议批准，同意公司为控股子公司四川利尔作物 1 根据《公司法》、《上市公司独立董事规则》、《深圳证券交易所股票上市规则》、 《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》、《公 司章程》及《公司独立董事工作制度》等相关法律、法规、规范性文件的有关规 定，作为公司的独立董事，经过审慎、认真的研究，现基于独立判断立场对有关 事项发表意见如下： 对公司关联方资金占用和对外担保的专项说明和独立意见 根据中国证监会、深圳证券交易所及公司治理制度等有关规定和要求，作为 公司的独立董事，我们本着对公司、全体股东负责的态度，对公司控股股东及其 他关联方占用公司资金情况和对外担保情况进行了认真的核查，现发表如下独立 意见： 1、报告期内，公司与控股股东及其他关联方的资金往来能够严格遵守相关 规定，不存在关联方违规占用公司资金的情况。 2、经公司 2020 年年度股东大会审议批准，同意公司为全资子公司广安利 尔化学有限公司（以下简称"广安利尔"）向银行申请的 6.32 亿元基本授信提供连 带责任担保。2021 年 4 月 8 ...

2023年1-6月非经营性资金占用及其他关联资金往来情况汇总表 上市公司名称：利尔化学股份有限公司 单位：万元 1 企业负责人： 尹英遂 主管会计工作的负责人： 颜宣 会计机构负责人： 羊晓莉 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核算的会计 | 2023年期初占用资金 | 2023年1-6月占用累 | 2023年1-6月占用资 | 2023年1-6月偿还累 | 2023年6月末占用资 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关联关系 | 科目 | 余额 | 计发生金额（不含利 息） | 金的利息(如有） | 计发生金额 | 金余额 | | | | | | | | | | | | | | 非经营性占用 | | 控股股东、实际控制人及 其附属企业 | | | | | | | | | | 非经营性占用 | | | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | - | - | - | - ...

利尔化学股份有限公司 证券代码：002258 证券简称：利尔化学 利尔化学股份有限公司投资者关系活动记录表 编号：2023-01 投资者关系活动 特定对象调研 □分析师会议 类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 海通证券：李智；四川发展证券基金：肖柏辰；弘尚资产：沙 人员姓名 正江；申万资管：许维伦；华能贵诚信托：赵文 时间 2023 年 7 月 19 日 地点 公司会议室 上市公司接待人 副总经理/董事会秘书：刘军 员姓名 董事会办公室：马媛 1、公司如何看待草铵膦市场？ 答：今年以来受竞争加剧以及农化行业周期的影响，公司 主要产品草铵膦价格下降较大，对公司业绩产生了较大的影 响。公司一直都看好草铵膦市场的成长空间，并全力保持竞争 优势。 2、公司精草铵膦项目的实施情况？ 答：目前公司正在按照建设计划有序推进，湖南津市 2 万 投资者关系活动 吨/年酶法精草铵膦项目预计 7 月开始试生产，荆州 1 万吨/ 主要内容介绍 年生化法精草铵膦项目已于今年 2 月获批开建。同时，公司加 快实施精草铵膦在海外多个国家的登记和市场布局工 ...

Financial Performance - The company's revenue for Q1 2023 was ¥2,442,238,961.34, a decrease of 6.53% compared to ¥2,612,935,661.17 in the same period last year[5] - Net profit attributable to shareholders was ¥274,738,068.68, down 48.58% from ¥534,331,688.15 year-on-year[5] - Basic earnings per share fell by 52.63% to ¥0.3432 from ¥0.7245 in the same period last year[5] - In Q1 2023, the net profit of Lier Chemical Co., Ltd. was CNY 342,029,168.28, a decrease of 42.2% compared to CNY 591,086,437.05 in Q1 2022[20] - The company's operating profit for Q1 2023 was CNY 403,195,762.83, down 42.6% from CNY 700,540,696.90 in the same period last year[20] - Total comprehensive income attributable to the parent company was CNY 274,738,068.68, down 48.6% from CNY 534,331,688.15 in Q1 2022[21] - Basic earnings per share for Q1 2023 were CNY 0.3432, a decrease of 52.6% from CNY 0.7245 in the same quarter last year[21] Cash Flow and Investments - The net cash flow from operating activities decreased by 39.47% to ¥123,955,733.40 from ¥204,771,003.87 in the previous year[5] - Cash flow from operating activities for Q1 2023 was CNY 123,955,733.40, a decline of 39.3% compared to CNY 204,771,003.87 in Q1 2022[22] - The company reported a net cash outflow from investing activities of CNY 703,479,356.00, worsening from CNY 309,682,113.96 in the previous year[23] Assets and Liabilities - Total assets increased by 6.20% to ¥13,663,798,916.24 compared to ¥12,866,345,708.15 at the end of the previous year[5] - Total liabilities increased to CNY 5,360,897,789.58 from CNY 4,483,335,442.13, an increase of 19.5%[18] - The company's equity attributable to shareholders decreased to CNY 7,148,862,668.32 from CNY 7,269,668,905.14, a decline of 1.7%[18] Operating Costs and Expenses - The total operating costs increased to CNY 2,044,281,131.94, up 6.5% from CNY 1,919,660,705.54 year-on-year[19] - The company incurred financial expenses of CNY 29,987,879.75, an increase of 21.1% from CNY 24,730,210.15 in Q1 2022[20] Research and Development - The company's R&D expenses rose by 55.49% to ¥9,752.61 from ¥6,272.32 in the previous year, indicating increased investment in innovation[11] - Research and development expenses increased to CNY 97,526,071.23, up 55.5% from CNY 62,723,198.01 in Q1 2022[20] Shareholder Information - The company recorded a total of 58,015 common shareholders at the end of the reporting period[12] Other Financial Metrics - The weighted average return on equity decreased to 3.71% from 10.19% in the previous year, indicating a decline in profitability[5] - The company reported a net profit margin decline due to increased costs, impacting overall profitability[19] - Cash and cash equivalents at the end of Q1 2023 were CNY 1,353,582,752.50, slightly down from CNY 1,333,738,748.44 at the end of Q1 2022[23] - Accounts receivable rose to CNY 1,628,660,818.38 from CNY 1,588,107,170.85 at the start of the year, indicating a growth of 2.3%[16] - Inventory decreased to CNY 1,642,894,394.51 from CNY 1,709,758,816.00, reflecting a decline of 3.9%[17] - Short-term borrowings increased significantly to CNY 295,209,305.55 from CNY 132,475,216.16, marking a rise of 123.5%[18] - The company reported a significant increase in prepayments, which rose by 63.34% to ¥14,608.30, primarily due to increased procurement of raw materials[11]

证券代码：002258 证券简称：利尔化学 公告编号：2023-010 利尔化学股份有限公司 关于举行 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 利尔化学股份有限公司（以下简称"公司"）已于2023年3月2日在 巨潮资讯网（www.cninfo.com.cn）上披露了《2022年年度报告》。 为使投资者更深入、全面地了解公司2022年度报告的内容，公司拟 于2023年3月21日（星期二）15:00-17:00举行2022年度网上业绩说 明会。 本次年度业绩说明会将采用网络远程的方式举行，投资者可登陆 深圳证券交易所"互动易"平台（http://irm.cninfo.com.cn），进入 "云访谈"栏目参与本次年度业绩说明会。 公司拟出席本次年度业绩说明会的人员有：公司董事长尹英遂先 生，独立董事李双海先生，副总经理、董事会秘书刘军先生，财务负 责人、财务总监颜宣先生。（如有特殊情况，参会人员可能进行调整。） 为充分尊重投资者、提升交流的针对性，现就公司2022年度业 绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和 ...

Market Presence and Growth - The company has a strong market presence with a global production capacity of 80% for its main herbicide product, Benzthiazuron, indicating significant market share and growth potential[1] - The company reported a stable market for its herbicide product, Dichloropicolinic Acid, with a global production capacity of 60% and established long-term partnerships with multinational companies[1] - The company has achieved early registration and steady growth in the North American and Chinese markets for its herbicide product, Acetochlor, with a growth potential of around 30%[1] - The company maintains a competitive edge in the pesticide market, ranking among the top 10 in national pesticide sales for four consecutive years and among the top 20 global agrochemical companies[10] - The company has established a solid sales network in South America for its herbicide products, indicating a strategic market expansion[1] - The company is focusing on expanding its market presence in over 30 countries, including the USA, Brazil, and Australia, to meet diverse customer needs[29] Financial Performance - In 2022, the company achieved a consolidated revenue of CNY 10.136 billion, representing a year-on-year growth of 56.08%[12] - The net profit attributable to the parent company reached CNY 1.812 billion, marking a 69.01% increase compared to the previous year, both figures being historical highs[12] - The pesticide segment contributed CNY 9.217 billion to the total revenue, accounting for 90.93% of the total, with a year-on-year growth of 53.66%[17] - International sales revenue surged by 103.50% year-on-year, amounting to CNY 6.158 billion, which represents 60.76% of total sales[19] - The gross profit margin for the pesticide segment was 32.71%, with a slight increase of 0.16% compared to the previous year[20] Research and Development - The company has a strong focus on research and development, with a significant number of its products registered for use in various international markets, enhancing its global competitiveness[4] - The company has invested in new product development, achieving notable technological advancements and improvements in production processes[15] - The company's R&D investment reached approximately CNY 416.15 million in 2022, a 58.39% increase from CNY 262.74 million in 2021[103] - Research and development expenses rose by 48.04% to approximately CNY 365.79 million in 2022, driven by increased personnel costs and R&D investments[102] - The company has a strong patent portfolio with multiple patents related to key technologies, enhancing its R&D capabilities[93] Production and Supply Chain - The company has a comprehensive supply chain with seven production bases, ensuring a multi-base supply guarantee for its main products, including the largest production capacity for Glyphosate in China[10] - The company has made significant advancements in production efficiency for key products, including glyphosate and chlorinated pyridine, ensuring market demand is met[15] - The company’s production management is based on a "sales-driven production" principle, aligning production plans with market demand[90] Environmental and Sustainability Efforts - The company has implemented a comprehensive environmental management system, achieving ISO 14001 certification, reflecting its commitment to sustainable practices[14] - The company plans to accelerate its transformation towards green development in response to stricter environmental regulations and industry restructuring[130] - The company has increased its environmental protection investments, ensuring compliance with national standards for waste emissions[159] - The management team emphasized a commitment to sustainability, with plans to reduce carbon emissions by 25% over the next five years[186] Strategic Partnerships and Collaborations - The company has established long-term strategic partnerships with major global agrochemical firms such as Corteva, BASF, and Nufarm, enhancing its market presence[29] - A strategic partnership with a leading technology firm was announced, aimed at co-developing innovative solutions for the agricultural sector[186] Risks and Challenges - The company faces risks related to market competition, raw material supply fluctuations, and environmental regulations, which investors should be aware of[31] - Raw material costs significantly impact operating costs and gross margins, with fluctuations due to supply chain disruptions and price increases affecting profitability[159] Cash Flow and Investments - The company's net cash flow from operating activities increased by 97.12% to approximately ¥2.60 billion compared to the previous year[88] - Investment activities generated a net cash outflow of approximately ¥2.20 billion, reflecting an increase of 180.57% year-on-year[88] - The total investment amount for the reporting period was approximately CNY 2.80 billion, a 139.91% increase from the previous year[108] Corporate Governance and Management - The company emphasizes the importance of corporate governance and has made revisions to its governance documents to enhance management efficiency[139] - The company has established a dedicated audit department with four full-time auditors to oversee internal controls and financial conditions[146] - The company maintains independence from its controlling shareholder, ensuring autonomous operations in business, personnel, and finance[168] Future Outlook - The company has provided a revenue guidance of 1.8 billion RMB for the fiscal year 2023, which reflects an expected growth of 20%[186] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence, with a budget allocation of 500 million RMB for this purpose[186]